| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d18e7904a7ab044ff4461118a5abf717 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate |
2012-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bebd36ed766cb0b94ca3d656ad1d374b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_718e77aff9f3d7d7e2c01747f6dd202c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_965cc973a7daaa5426c94ede34cb852a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2de49c18efc974c0e38b3652b430d87d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f258d94e050c1f699d12ba234d676e6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7028c2693e1d9c8c997d0c4cbfb6d2c |
| publicationDate |
2013-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2853495-A1 |
| titleOfInvention |
Methods and compositions for treating hepatitis c virus |
| abstract |
Disclosed herein is a method of treating a subject infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. Also disclosed herein is a composition useful for the treatment of hepatitis C virus infection, said composition comprising an effective amount of GS-7977 and an effective amount of ribavirin. |
| priorityDate |
2011-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |